Fernand Labrie
Founder and CEO
EndoCeutics
Canada
Biography
Professor Labrie is one of the most accomplished scholars in the international scientific community. He has authored more than 1280 scientific publications with a total of over 50 000 citations, which makes him the most cited Canadian scientist of all disciplines by other scientists in the world. Professor Labrie’s first major contribution to clinical medicine has been in the field of prostate cancer by the design and clinical development of gonadotropin-releasing hormone (GnRH) agonists for the treatment of prostate cancer. This ground-breaking treatment strategy, generally referred to as "reversible chemical castration", has replaced the surgical removal of the testes (orchiectomy) and the use of high doses of female hormones (estrogens), which had so-far been the standard treatments for prostate cancer. With GnRH agonists, both the psychological disadvantages of orchiectomy and the cardiovascular complications of high estrogen doses have been eliminated and the quality of life of hundreds of thousands of prostate cancer patients has been and continues to be dramatically improved.
Research Interest
His research interest lies in Endocrinology